Save time: USP 800 Risk Assessment **On-Line**

DACARBAZINE INTRAVENOUS SOLUTION

General Information

Brand Name

DTIC-Dome

Generic Name

Dacarbazine Intravenous Solution

NIOSH Hazardous Risk Group

1

Type of Hazardous Drug

Antineoplastic

Risk of Exposure

Category 1 (Antineoplastic) Recommendation to follow all USP 800 Procedures

Dosage

Dosage Form

IV Injection Solution for Injection

Dosage Form Classification

Solution for Injection

Drug Administration

Follow USP 800 guidelines which include the recommendation of using a CSTD (closed system transfer device), two pairs of powder free ASTM standard D6978 rated chemotherapy gloves, and a gown made of polyethylene-coated polypropylene or other laminate material that close in the back, have long sleeves, and closed cuffs that are elastic or knit. Additional PPE may be warranted depending on your organization's occupational safety plan.

Receiving + Storage

Receiving

Unpack in a negative pressure location between 0.01 and 0.03 inches of water column relative to adjacent areas.. Utilize single ASTM D6978 glove. Have a spill kit and/or respirator accessible in receiving area.

Storage Recommendations

Store in an externally vented, negative pressure room with at least 12 air changes per hour (ACH). Product requiring refrigeration shall be stored in a separate dedicated refrigerator within the negative pressure space.

Packaging + Compounding

Packaging Manipulation

Purchase in UD ready to administer packaging from manufacturer when feasible. Any further manipulation of ready to administer sterile packaging should follow sterile compounding recommendations as applicable in USP 797 & USP 800.

Compounding (Sterile)

All sterile hazardous drugs requiring manipulation must be performed in a C-PEC (BSC/CACI) that provides ISO Class 5 or better air quality. The C-PEC must be located in a C-SEC which should be in an ISO Class 7 buffer room with an ISO Class 7 ante-room (preferred). The ISO Class 7 C-SEC should have fixed walls, HEPA filtered air supply, externally vented, achieve 30 ACPH, and negative pressure between 0.01 and 0.03 inches of water column relative to adjacent areas. Personnel should done PPE as applicable per USP 797 & USP 800 guidelines. The use of CSTD as an additional containment strategy is also recommended but at a minimum compounding must be performed utilizing negative pressure sterile technique.

Compounding (Non-Sterile)

Not applicable. Product form is sterile.

Deactivation

Cleaning

Shall perform deactivation, decontamination, clean, and disinfection as applicable for the compounding situation (EPA registered oxidizer, peroxide, germicidal detergent, and sterile alcohol)

Reference

SDS

https://www.caymanchem.com/msdss/21877m.pdf

AHFS Classification

10:00.00 — Antineoplastic Agents

PARTNERS *in* PHARMACY™
www.partnersinpharmacy.com
Print Date: Saturday 1st December 2018

We are your PARTNERS *in* PHARMACY

web: www.PartnersInPharmacy.com
e-mail: info@PartnersInPharmacy.com
tel: 844-778-6377 (844-PRTNERS)